File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo

TitleRegulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo
Authors
KeywordsChinese medicine decoction
colon cancer
metastasis and multidrug resistance
proliferation
Tian-Xian liquid
Issue Date2011
PublisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510
Citation
Integrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69 How to Cite?
AbstractEthnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011.
Persistent Identifierhttp://hdl.handle.net/10722/127608
ISSN
2021 Impact Factor: 3.077
2020 SCImago Journal Rankings: 0.730
ISI Accession Number ID
Funding AgencyGrant Number
Seed Funding Programme for Applied Research200807160015
Small Project Funding200807176239
University of Hong Kong
China-Japan Feida Union Company Limited
Funding Information:

This research was supported in part by a grant from Seed Funding Programme for Applied Research (no. 200807160015), Small Project Funding (no. 200807176239), the University of Hong Kong, and the contract research funding from China-Japan Feida Union Company Limited.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorSze, SCWen_HK
dc.contributor.authorWong, KLen_HK
dc.contributor.authorLiu, WKen_HK
dc.contributor.authorNg, TBen_HK
dc.contributor.authorWong, JHen_HK
dc.contributor.authorCheung, HPen_HK
dc.contributor.authorYow, CMLen_HK
dc.contributor.authorChu, ESMen_HK
dc.contributor.authorLiu, Qen_HK
dc.contributor.authorHu, YMen_HK
dc.contributor.authorTsang, KWen_HK
dc.contributor.authorLee, WSen_HK
dc.contributor.authorTong, Yen_HK
dc.date.accessioned2010-10-31T13:35:23Z-
dc.date.available2010-10-31T13:35:23Z-
dc.date.issued2011en_HK
dc.identifier.citationIntegrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69en_HK
dc.identifier.issn1534-7354en_HK
dc.identifier.urihttp://hdl.handle.net/10722/127608-
dc.description.abstractEthnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011.en_HK
dc.languageengen_HK
dc.publisherSage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510en_HK
dc.relation.ispartofIntegrative Cancer Therapiesen_HK
dc.rightsIntegrative Cancer Therapies. Copyright © Sage Publications, Inc..-
dc.subjectChinese medicine decoctionen_HK
dc.subjectcolon canceren_HK
dc.subjectmetastasis and multidrug resistanceen_HK
dc.subjectproliferationen_HK
dc.subjectTian-Xian liquiden_HK
dc.subject.meshColonic Neoplasms - drug therapy - genetics - metabolism - pathology-
dc.subject.meshCyclin-Dependent Kinase Inhibitor p21 - biosynthesis - genetics-
dc.subject.meshDrugs, Chinese Herbal - adverse effects - chemistry - pharmacology-
dc.subject.meshMatrix Metalloproteinase 1 - biosynthesis - genetics-
dc.subject.meshP-Glycoprotein - biosynthesis - genetics-
dc.titleRegulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivoen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1534-7354&volume=&spage=DOI:10.1177/1534735410378743&epage=&date=2010&atitle=Regulation+of+p21,+MMP-1+and+MDR-1+expression+in+Human+colon+carcinoma+HT29+by+Tian+Xian+Liquid,+a+Chinese+Medicine+Formula,+in+vitro+and+in+vivoen_HK
dc.identifier.emailSze, SCW: stephens@hku.hken_HK
dc.identifier.emailTong, Y: tongyao@hku.hken_HK
dc.identifier.authoritySze, SCW=rp00514en_HK
dc.identifier.authorityTong, Y=rp00509en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1177/1534735410378743en_HK
dc.identifier.pmid20702488-
dc.identifier.scopuseid_2-s2.0-79953704228en_HK
dc.identifier.hkuros197172en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79953704228&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue1en_HK
dc.identifier.spage58en_HK
dc.identifier.epage69en_HK
dc.identifier.eissn1552-695X-
dc.identifier.isiWOS:000289157000006-
dc.publisher.placeUnited Statesen_HK
dc.relation.projectMechanical Study of Tian Xian Liquid (TXL), Chinese Medicine Formula, in Treatment of Colon Cancer in vitro-
dc.relation.projectBioactive components of Tian Xian Liquid as a potential drug candidate for the treatment of colon cancer-
dc.identifier.scopusauthoridSze, SCW=23482617000en_HK
dc.identifier.scopusauthoridWong, KL=47861480700en_HK
dc.identifier.scopusauthoridLiu, WK=37045953300en_HK
dc.identifier.scopusauthoridNg, TB=35311803300en_HK
dc.identifier.scopusauthoridWong, JH=34874358200en_HK
dc.identifier.scopusauthoridCheung, HP=37033470100en_HK
dc.identifier.scopusauthoridYow, CML=47861516500en_HK
dc.identifier.scopusauthoridChu, ESM=13807807000en_HK
dc.identifier.scopusauthoridLiu, Q=36063708000en_HK
dc.identifier.scopusauthoridHu, YM=7407116890en_HK
dc.identifier.scopusauthoridTsang, KW=47861536800en_HK
dc.identifier.scopusauthoridLee, WS=12788473400en_HK
dc.identifier.scopusauthoridTong, Y=9045384000en_HK
dc.identifier.issnl1534-7354-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats